perimenopause and tirzepatide If weight loss slows on during perimenopause, that isn’t “noncompliance.”, It’s biology colliding with a system that wasn’t built to explain it., #obesitydoctor #womenshealth PSA for all the women

Trump sent letters to 17 drug companies including Lilly telling them to increase prices in non-U.S

Foundayo (Orforglipron) Foundayo, which contains orforglipron, is a newer FDA-approved once-daily oral GLP-1 receptor agonist

Common and Distinct Adverse Effect Profiles Both tirzepatide and semaglutide share gastrointestinal adverse effects as the primary tolerability concern during dose escalation

A 2014 study published in the Journal of Pharmaceutical Sciences found that solvent choice and injection technique were among the most significant variables affecting lyophilized peptide recovery and activity retention

Accurate Tracking: InBody provides precise measurements that help you track changes in your body composition over time